newsfilter
← Latest News
GlobeNewswire·

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable debt securities,